Scholars Central

Conference abstractPublished 23 Nov 2012

Development of new anticancer agents

Authors: Ahmed Kamal

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cancer continues to be a major health concern and a number of deaths are caused by cancer that is second only to cardiovascular diseases. The development of compounds that target genes involved in cancer pathogenesis is a potential area of cancer drug discovery. A number of anticancer drugs employed clinically exert their effect by inhibiting nucleic acid (DNA or RNA) or protein synthesis. It is evident that DNA is an important cellular target for many anticancer agents. Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are naturally occurring compounds isolated from various Streptomyces species. The PBDs exert their biological activity through covalent binding within the minor groove of DNA. Several PBD conjugates have been synthesized to investigate the detailed biological aspects relating to the mechanism of action. Some of the potent molecules like PBD-quinazolinones and PBD-diaryloxadiazoles have been evaluated for their in vivo efficacy studies. These studies suggest that such PBD conjugates have promising anticancer activity. Some of the PBD conjugates act as activators of p53 and suppressors of NF-κB and thereby they could be considered as promising anticancer agents with improved potential for the suppression of tumours. To improve the selectivity as well as stability, some new β-galactoside prodrugs of PBDs have been synthesized and evaluated for their potential use in selective therapy of solid tumors by ADEPT and PMT protocols. Another important property of these molecules is their enhanced water solubility and stability, which are essential for a molecule to be an effective drug.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ahmed Kamal”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels